Biotech has shown an incredibly bright spot in the 2022 startup correction.

There is no startup sector. 2022 has been completely free of market volatility – except perhaps AI – but some have proved stronger than others. Biotech was one of the luckiest.

By 2022, the sector recorded 1,054 U.S. deals, worth a combined $30.7 billion, according to Pitchbook data. These figures fall short of the 1,415 biotech deals in 2021 totaling $39 billion. But the decline wasn’t as bad as we found: Biotech saw a more modest decline in year-over-year investment (21%) than many other sectors, including fintech (37.7%), consumer tech (53%) and enterprise tech (33%). %)

Comparing the results of any sector to 2021 is a bit different, as that year was the last start-up growth. More conservative than the 2020s, 1,143 biotech deals worth $29.6 billion were completed last year.

US biotech deals set new records in 2022 for both average deal size, $33.5 million, and average value, $38 million.

As biotech investors felt the general economic climate was tight last year — and tourist investors were shunning the sector like other sectors — many weren’t impressed that the category fared better than others. Boozy Industries for a few key reasons.

Source link

Related posts

Leave a Comment

4 × 4 =